Altimmune's Pemvidutide Shows Positive Phase 2 Results for Alcohol Use Disorder

Altimmune announced positive topline results from its RECLAIM Phase 2 trial for pemvidutide, an investigational drug for moderate to severe alcohol use disorder. The trial met its primary endpoint, showing a statistically significant reduction in heavy drinking days and positive results across secondary endpoints. This development could offer a new treatment option for AUD, addressing a significant public health challenge.